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ing agent esmolol, added to standard oxygenated blood
cardioplegia, improved myocardial function after weaning
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Design: A block-randomized, blinded study.
Setting: A university laboratory.
Participants: Twenty anesthetized pigs, Norwegian
Landrace.
Interventions: After cardiopulmonary bypass, cardiac
arrest was induced with cold (121C), oxygenated blood
cardioplegia, enriched with either esmolol or vehicle,
repeated every 20 minutes. After 100 minutes the heart
was reperfused and weaned.
Measurements and Main Results: Left ventricular function
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684 Journal of Cardiothoanimals v 57  4 mmHg (po 0.001) in controls after 3 hours.
Radial peak ejection strain rate also was increased by esmolol;
6.0  1.0 s1 v 2.9  0.3 s1 (po 0.001) in subendocardium
and 3.9  0.5 s1 v 2.3  0.2 s1 (po 0.005) in the midmyo-
cardium. Cardiac index was increased, 4.0  0.2 L/min/m2 by
esmolol v 3.3  0.1 L/min/m2 for controls (po 0.05). Isovolu-
metric relaxation time constant was reduced by esmolol,
23  1 ms v 261 ms (po 0.025). Troponin-T did not differ
and was 339  48 ng/L for the esmolol group and 357  55
ng/L for the control group (p ¼ 0.81).
Conclusions: Esmolol added to blood cardioplegia pre-
served systolic cardiac function during the ﬁrst 3 hours after
reperfusion in a porcine model with 100 minutes of cardio-
plegic arrest.
& 2015 The Authors. Published by Elsevier Inc. All rights
reserved.
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cardiopulmonary bypass, beta-blockadeIN NUMEROUS CLINICAL AND EXPERIMENTAL stud-ies, β-adrenergic blocking agents are found to be protective both
functionally and structurally in myocardium undergoing ischemia
and reperfusion.1–3 This cardioprotective effect also may be
beneﬁcial during cardiopulmonary bypass (CPB) and cardioplegic
arrest. However, the cardiodepressive effects of these agents
potentially may prolong weaning and lead to an inadequate cardiac
response in the postoperative phase. Therefore, special attention has
been drawn to the ultra short-acting β-blocker esmolol.
From a cardioprotective point of view, continuous myocar-
dial perfusion with high concentrations of esmolol may be
advantageous compared to potassium-based cardioplegia, to
facilitate acceptable surgical conditions with little or no
myocardial movement.4–7 Use of lower systemic concentra-
tions of esmolol before, during, or after CPB and cardioplegic
arrest in combination with commonly used cardioplegic regi-
mens also have been shown to be beneﬁcial, both experimen-
tally and clinically.8–10 In isolated hearts both anoxia and
ischemia release catecholamine stores, resulting in lipolysis andmyocardial tissue damage.11–13 Crystalloid cardioplegia pre-
serves myocardial catecholamine stores.14 Esmolol may further
reduce the potential ischemic and reperfusion injury by
inhibiting the effects of the endogenous release of catechol-
amines. When added to repeated oxygenated blood cardiople-
gia, direct intracoronary delivery of esmolol during the
cardioplegic perfusions exposes the myocardium to esmolol
with a reduced total systemic dose. To the authors’ knowledge,
only 1 study has used esmolol as an additive to cold blood
cardioplegia. In patients urgently operated for unstable angina,
the addition of esmolol did not affect myocardial tissue damage
judged by troponin-I, CK-MB fraction, and lactate release.15
However, postoperative cardiac function was not evaluated.
Repeated antegrade, cold, oxygenated, blood cardioplegia is
often the preferred method used to facilitate cardioplegic arrest
and myocardial protection.16 In this experimental study, the
authors hypothesized that esmolol as an additive to standard
potassium-based blood cardioplegia would improve the post-
operative cardiac function. Pigs were subjected to CPB and
cardioplegic arrest for 100 minutes during tepid general hypo-
thermia in a protocol mimicking a clinical setting. Cardiac
function was evaluated with regional and global variables for
the ﬁrst 3 hours after aortic declamping and reperfusion.METHODS
The experiments were performed using 24 pigs (Norwegian
Landrace) of either sex weighing 43  4 kg (SD). Animals were
acclimated for at least 7 days. Before surgery animals were fasted
overnight, but with access to water. All procedures were performed
in accordance with international guidelines described in the
European Communities Council Directive of 2010 (63/EU). The
experimental protocol was approved by the Norwegian State
Commission for Laboratory Animals (project No. 20092088).
After premedication with ketamine, 20 mg/kg, diazepam, 10
mg, and atropine, 1 mg IM, animals brieﬂy were ventilatedracic and Vascular Anesthesia, Vol 29, No 3 (June), 2015: pp 684–693
Table 1. Final Concentrations in Blood Cardioplegic Perfusate
High Dose Low Dose Total Dose
Kþ 22 mM 14 mM 877 µmol/Kg
Mg2þ 16 mM 9 mM 719 µmol/Kg
Cl- 134 mM 120 mM 2352 µmol/Kg
Procaine 0.8 mM 0.4 mM 37 µmol/Kg
Esmolol 34 mM 19 mM 1.6 µmol/Kg
ESMOLOL PRESERVES CARDIAC FUNCTION AFTER CPB 685with isoﬂurane, 3% in oxygen, allowing cannulation of 2 ear
veins. General anesthesia was induced and maintained by
loading doses and continuous infusions of fentanyl, 0.02 mg/
kg and 0.02 mg/kg/h, midazolam, 0.3 mg/kg and 0.3 mg/kg/h,
vecuronium, 0.4 mg/kg and 0.2 mg/kg/h, and pentobarbital, 15
mg/kg and 4 mg/kg/h. A tracheotomy was performed and the
lungs of each pig were ventilated (Julian, Dräger, Lübeck,
Germany) with 57% N2O and oxygen, with a tidal volume of
11 mL/kg. The end-tidal CO2 was kept within the range of 5.0
to 5.7 kPa (38 to 43 mmHg) by respiratory rate adjustments.
Further evaluation of this anesthetic protocol, justifying the
safe use of a neuromuscular blocker in young pigs, can be
found elsewhere.17 At the end of the experiments, still under
general anesthesia, animals were euthanized by saturated
potassium chloride injected into the left atrium.
Surgical Preparation and Instrumentation
The right femoral artery and vein were exposed surgically
and cannulated. A suprapubic urine catheter was inserted into
the bladder. Following midline sternotomy and pericardiot-
omy, a band was placed loosely around the inferior caval vein,
allowing dynamic preload reductions. A Portex catheter placed
into the left atrium was used for microsphere injections.
Sutures later needed for bypass cannulation were prepared.
A Swan-Ganz catheter (139H-7.5F; Edward Lifesciences Inc.,
Irvine, CA) was advanced from the right internal thoracic vein
to the pulmonary artery, connected to a continuous cardiac
output computer (Vigilance I; Edward Lifesciences Inc.) and
pressure transducers (SensoNor, Horten, Norway), obtaining
central venous and pulmonary artery pressures. Central aortic
pressure was measured by a pressure-tip catheter (MPC-500;
Millar Corp., Houston, TX) placed in the proximal aorta from
the left internal thoracic artery. The pressure-conductance
catheter (SPR 788; Millar Corp.), connected to a signal
conditioning unit (Sigma 5; CD Leycom, Zoetermeer, the
Netherlands), was placed via the apex through the left ventricle
and through the aortic valve. Correct position was conﬁrmed
by echocardiography (Vivid E9; GE Vingmed Ultrasound,
Horten, Norway) and any distal conductance segments with
paradox volume signals were excluded. All hemodynamic
signals were digitized and recorded with a signal conditioner
unit (ACQ-7700; Data Sciences International, St. Paul, MN).
Animals were allowed to stabilize for 15 minutes before
baseline data were obtained.
Cardiopulmonary Bypass
Animals were cannulated for CPB with an 18F arterial
cannula (Medtronic Inc., Minneapolis, MN) in the brachioce-
phalic artery and a 29F cavoatrial 3-stage cannula (Medtronic
Inc.) placed from the right atrial appendage. After tepid CPB
ﬂow (90 mL/min/kg) for a short time, mixing blood and prime
volume (1200 mL Ringer’s acetate), an arterial blood gas was
drawn and the aorta was cross-clamped. Oxygenated cold blood
cardioplegia, 7% of initial CPB ﬂow (6.3 mL/min/kg), was
administered in the aortic root with an initial “high dose” for 3
minutes followed by 2 minutes of “low dose” every 20 minutes
(Table 1). Following the ﬁrst cardioplegia infusion, a 17F left
ventricular venting catheter was placed through the left atrium.The animal core temperature was allowed to drift. When
reaching 351C or no later than after 20 minutes, CPB ﬂow
was reduced to 72 mL/min/kg. Following the last cardioplegia
infusion, CPB ﬂow was reset to 90 mL/min/kg and rewarming
was commenced. After 100 minutes the aorta was de-
clamped, and animals weaned from CPB within 20 minutes.
If needed, ventricular ﬁbrillations were electroconverted. No
other antiarrhythmic intervention was allowed in the protocol.
The animals were monitored for 3 hours after aortic declamping.
Design
A block randomized controlled study was performed.
Researchers were unaware of the randomization code both
during surgery and analysis. Excluded animals were replaced
by consecutive experiments until a total of 10 animals in each
group were included. The cardioplegic concentrate (1000 mL)
was enriched with 5 mL, 10 mg/mL, of esmolol (Brevibloc,
Baxter AS, Oslo, Norway) for the intervention group or 5 mL
of vehicle for the control group. A total of 0.467 mg/kg (1.6
mmol/kg) of esmolol was administered to pigs in the inter-
vention group. The freshly mixed cardioplegic solution, 121C,
was delivered with a dual-head pump and separate cooling.
This will expose the myocardium to concentrations avoiding
signiﬁcant inﬂuence from inhibition of L-type Ca2þ channels
and fast Naþ channels (Table 1).18
Measurements of Cardiac and Hemodynamic
Function
Measurements were performed at baseline and 1, 2, and 3
hours after aortic declamping. At each point, arterial blood
gases and serum for troponin-T measurements were drawn.
Injections of ﬂuorescent microspheres (Dye-Trak “F” s,
Triton Technology Inc., San Diego, CA) were performed with
a concurrent sampling of reference arterial blood with a
constant rate extraction pump for regional tissue blood ﬂow
measurements.19 General hemodynamics were analyzed with
Ponemah Physiology Platform v. 4.90 (Data Sciences Interna-
tional). PV-loop data were exported and analyzed with custom-
made software. Hemodynamic variables were averaged over 5-
8 consecutive heart beats during a stable situation. The time
constant of isovolumetric relaxation, τ, was calculated accord-
ing to Raff and Glantz.20 From 6-10 consecutive cardiac cycles
during a dynamic preload reduction, load-independent variables
were obtained (Fig 1). Systolic function was described by the
left ventricular end-systolic pressure-volume relationship
(ESPVR) and preload-recruitable stroke work (PRSW). Corre-
spondingly, diastolic compliance was expressed by the linear
and the logarithmic end-diastolic pressure-volume relationships
(EDPVRlin and β).21,22 The median correlation coefﬁcient for
Fig 1. Typical waveforms (left panels) during a dynamic preload reduction recording with end-diastole (dashed lines) and end-systole (dotted
line), corresponding pressure-volume loops (upper right panel) with end-systolic pressure-volume relation (dashed line) and logarithmic end-
diastolic pressure-volume relation (dotted line) and stroke work as a function of end-diastolic volume with the preload-recruitable stroke work
relation (lower right panel). V and P ¼ left ventricular volume and pressure; dP/dt ¼ ﬁrst derivative of left ventricular pressure; LV ¼ left
ventricle; SW ¼ stroke work; EDV ¼ end-diastolic volume.
DAHLE ET AL686ESPVR was 0.994 (0.994; 0.982), for PRSW 0.999 (0.999;
0.997), for EDPVRlin 0.989 (0.989; 0.969) and for β 0.986
(0.986; 0.962). Parallel conductance was determined by the
hypertonic saline injection method (3  5 mL, 10 % NaCl).23
Variables based on cardiac volumes were normalized for body
surface area.24
Using a 6-MHz sector probe (6S, GE Vingmed Ultra-
sound) and a 3 cm thick silicon pad as an offset, an epicardial
short-axis view was obtained at the papillary muscle level. By
reducing the depth and narrowing the sector, a detailed TDI
recording of the left ventricular anterior wall was obtained for
radial strain analysis. From an apical 5-chamber long-axis
view, including the left ventricular outﬂow tract and the aortic
valve, a pulsed Doppler recording was used to obtain the
valve opening and closure, deﬁning start of ejection and end-
systole from the Doppler spectrum. All echocardiographic
recordings were carried out during respirator shut-off and
were optimized for high frame rate. Echocardiographic
analyses were performed using EchoPac BT11 (GE Vingmed
Ultrasound). Using one cardiac cycle, the short-axis TDI
cineloops were analyzed for radial peak systolic strain and
radial peak ejection strain rate in 3 manually traced regions of
interests (2  6 mm, strain length 2 mm) corresponding to the
subendocardial, midmyocardial, and epicardial wall layers.25
Median TDI frame rate was 345 (395; 288) frames/s. During
isovolumetric contraction, peak strain rate displayed unphy-
siologically peak values in a few of the open chest, open
pericardium animals.25 Peak strain rate was, therefore, meas-
ured only during the ejection phase.Tissue and Blood Samples
Immediately after euthanasia, the hearts were removed and
tissue samples from the subendocardial, midmyocardial, and
subepicardial layers were snap-frozen in liquid nitrogen and
later stored at -801C. Samples were obtained for transmural
tissue water content and regional tissue blood ﬂow. The
samples used for regional blood ﬂow estimation were hydro-
lyzed, spheres ﬁltered, colors dissolved, and analyzed on a
ﬂuorospectrophotometer as described elsewhere.19 Myocardial
water content was calculated as fraction of wet weight after
drying samples for 3 weeks at 601C.
As markers for apoptotic activity, tissue from all 3 wall layers
were analyzed for caspase-3 cleavage by Western blotting (BD-
Pharmingen, San Diego, CA), using GAPDH (Santa Cruz Bio-
technology, Santa Cruz, CA) to verify equal loading conditions.
Caspase-3 activity was determined using the Caspase-3 Colori-
metric Assay Kit (BioVision Inc., Milpitas, CA). Tissue was
homogenized and lysis performed according to the manufacturer’s
instructions, and triplet samples containing 400 mg of total protein,
measured by the Quick Start Bradford Protein Assay (Bio-Rad,
Hercules, CA), were incubated for 2 hours before ﬂuorometric
readings. Troponin-T was analyzed according to the hospital
clinical routine (Troponin-T hs ®, Roche Diagnostics GmbH,
Mannheim, Germany).
Statistical Analysis
Data were analyzed by SPSS v. 20 (IBM, Armonk, NY).
Values are given as mean  SEM or median (75-percentile;
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water content, regional blood ﬂow, caspase-3 activity and
troponin-T values at the end of the experiments were analyzed
for normal distribution by Kolmogorov-Smirnov tests and
equal variance by Levene median tests, and compared with
two-sample t-test or Wilcoxon-Mann-Whitney test when appro-
priate. Variables obtained after declamping were analyzed by
two-way analysis of variance for repeated measurements (RM-
ANOVA) with time as within factor (pw) and treatment as
grouping factor (pg). If Mauchly’s test of sphericity was
signiﬁcant (po 0.05), the Greenhouse-Geisser adjustment of
degrees of freedom was selected. If the level of signiﬁcance for
the interaction between time and group (pi) was less than 0.1,
tests for simple main effects were performed at appropriate
factors levels. Cell means ﬁnally were compared with
Newman-Keuls multiple contrast tests when appropriate. A p
value less than 0.05 was considered statistically signiﬁcant.
RESULTS
Four animals were excluded because of reasons not directly
related to technical failure. In one animal from each group, multiple
supraventricular arrhythmias made measurements with conductance
catheter and echocardiography meaningless. One animal in the
esmolol group developed severe pulmonary hypertension followed
by pulmonary edema shortly after weaning. One animal in the
control group suffered severe arterial hypoxia (PaO2o 6 kPa/45
mmHg) and pulmonary hypertension after weaning due to an atrial
septal defect found by dissection of the heart.
Characteristics During Baseline and CPB
At baseline, there were no signiﬁcant differences between
groups regarding cardiac and hemodynamic variables (Table 2,
Figs 2 and 3). No group differences were found with regard to
body weight, rectal temperature, diuresis, arterial blood gases
(alpha-stat), troponin-T or respirator settings. Furthermore, there
were no signiﬁcant differences between groups in systemic meanTable 2. Baseline Variables B
Variable Esmolol (n ¼ 10)
HR (beats/min) 86  7
LV-ESP (mmHg) 107  4
LV-ESVi (mL/m
2) 36  3
LV-EDP (mmHg) 8.8  0.9
LV-EDVi (mL/m
2) 80  4
SVi (mL/m
2) 44  1
LV-SWi (mmHg/mL/m2) 3963  154
LV-dP/dtmin (mmHg/s) -2450  167
β 0.036  0.004
EDPVRlin (mmHg/mL) 0.16 (0.25 ; 0.15)
MAP (mmHg) 96  5
CVP (mmHg) 4.7  0.9
PAP (mmHg) 15  2
LV-tissue ﬂow (mL/min/g) 0.92  0.07
RV-tissue ﬂow (mL/min/g) 0.72  0.07
NOTE. Values are mean  SEM or median (75-percentile; 25-percentile)
Abbreviations: β and EDPVRlin, slope of logarithmic and lineary ﬁtted e
pressure; dP/dtmin, peak minimum of ﬁrst derivative of ventricular pressu
systolic pressure; ESV, end-systolic volume; HR, heart rate; i, value indexed
p, p values from two-sample t-tests or Mann-Whitney Rank Sum Tests; P
volume; SW, stroke work.arterial pressure (MAP), rectal temperature or arterial blood gas
values during aortic cross-clamping (Table 3).
Cardiovascular Effects Between Groups After Aortic
Declamping
Stroke volume decreased gradually in controls after 2 hours
(po 0.01) and decreased further (po 0.05) after 3 hours of
reperfusion (Table 4). One hour after declamping, cardiac index
and the peak positive of the ﬁrst derivative of left ventricular
pressure, dP/dtmax, did not differ between groups but decreased in
controls to values lower (po 0.05 for both) than in esmolol-
treated animals 3 hours after declamping (Fig 2). Ejection fraction
(EF) signiﬁcantly increased in the esmolol group between 1 and 3
hours after declamping, but remained unchanged in controls.
PRSW gradually increased in the esmolol group from 1 to 3
hours, with no changes in the control group, demonstrating a group
difference at 3 hours after declamping. The relaxation constant, τ,
decreased in both groups from 1 to 2 hours (po 0.025) after
declamping, further decreasing in the esmolol group only, leading
to a signiﬁcant group difference after 3 hours (po 0.025).
Subendocardial peak systolic strain decreased in the control
group and remained unchanged in esmolol-treated animals,
with a signiﬁcant group difference after 3 hours of reperfusion
(Fig 3). Peak ejection strain rate in the subendo- and
midmyocardial layers increased gradually during the ﬁrst 3
hours after declamping in esmolol-treated animals as opposed
to no difference in the control group. The two study groups
differed signiﬁcantly after 3 hours.
Hemodynamic Changes Over Time Unrelated to
Intervention
One hour after declamping no signiﬁcant differences could be
demonstrated between the esmolol and the control group (Table 4,
Figs 2 and 3). Heart rate gradually increased in both groups from an
average mean value of 103  5 beats/min (n = 20) at 1 hour to
115  7 beats/min (po 0.025) at 2 hours and further to 125  7efore Cardioplegic Arrest
Control (n ¼ 10) Statistics p Value
85  6 0.88
114  8 0.44
34  5 0.76
10.5  1.0 0.22
76  6 0.58
42  2 0.37
3931  235 0.91
-2400  218 0.86
0.034  0.005 0.81
0.19 (0.26 ; 0.15) 0.43
98  7 0.82
4.2  0.5 0.64
15  3 0.99
0.88  0.10 0.60
0.61  0.06 0.23
.
nd-diastolic pressure-volume relationship; CVP, mean central venous
re; EDP, end-diastolic pressure; EDV, end-diastolic volume; ESP, end-
for body surface area; LV, left ventricle; MAP, mean arterial pressure;
AP, mean pulmonary artery pressure; RV, right ventricle; SV, stroke
Fig 2. Cardiac Index, peak positive of ﬁrst derivative of left ventricular pressure (dP/dtmax), ejection fraction (EF), time constant of
isovolumetric relaxation (τ), slope of preload-recruitable stroke work (PRSW) and slope of end-systolic pressure-volume relationship (ESPVR) at
baseline, 1 hour, 2 hours and 3 hours after aortic declamping. Values are mean  SEM or median with quartiles. pw, pg, pi ¼ signiﬁcance levels
within, between groups and for interaction by RM-ANOVA. * ¼ signiﬁcant difference between group means at 3 hours; § ¼ signiﬁcantly different
from 1 and 2 hours within same group; # ¼ signiﬁcantly different from 1 hour within same group with Newman-Keuls multiple contrast tests.
DAHLE ET AL688beats/min at 3 hours (po 0.05). Furthermore, there were overall
decreases in ventricular pressures and volumes; indexed end-systolic
volume decreased from 22  2 mL/m2 at 1 hour to 16  2 mL/m2
at 3 hours (po 0.01), whereas the end-systolic pressure and end-
diastolic pressure and volume at 1 hour, 85  4 mmHg, 6.9  0.4
mmHg and 60  3 mL/m2, were signiﬁcantly reduced already at 2
hours after declamping to 73  3 mmHg (po 0.01), 5.7 0.4mmHg (po 0.025) and 52  3 mL/m2 (po 0.001), respectively.
The stroke work and peak negative of the ﬁrst derivative of left
ventricular pressure, dP/dtmin, did not differ between groups after
reperfusion and decreased from 2,796 209 mmHg/mL/m2 at 1
hour to 2,150  125 mmHg/mL/m2 after 2 hours for stroke work
(po 0.005) and increased from -1,977  139 mmHg/s to
-1,652 96 mmHg/s for dP/dtmin (po 0.01) (n = 20 for all).
Fig 3. Radial peak systolic strain and radial peak ejection strain rate through left anterior ventricular wall at baseline and 1, 2, and 3 hours
after aortic cross-clamp release. Values are mean  SEM or medians with quartiles. pw, pg, pi ¼ signiﬁcance levels within, between groups and
for interaction by RM-ANOVA. * ¼ signiﬁcant difference between group means at 3 hours; § ¼ signiﬁcantly different from 1 and 2 hours within
the same group; # ¼ signiﬁcantly different from 1 hour within same group with Newman-Keuls multiple contrast tests.
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Table 3. Mean Arterial Pressure, Temperature, Hemoglobin and Arterial Blood Gases During Cardiopulmonary Bypass and Aortic Clamp in
2 Groups of Pigs With 100 Minutes of Cardioplegic Arrest
Variable 2 min before X-clamp 50 min X-clamp 98 min X-Clamp Statistics
MAP (mmHg)
Esmolol 78  4 51  3 64  4 pwo 0.001, pg ¼ 0.92, pi ¼ 0.59
Control 83  8 49  6 60  4
Temprect (1C)
Esmolol 38.6  0.3 34.9  0.1 37.8  0.1 pwo 0.001, pg ¼ 0.24, pi ¼ 0.79
Control 38.9  0.3 35.0  0.1 38.2  0.3
Hb (g/dL)
Esmolol 7.6  0.2 8.6  0.4 8.9  0.2 pwo 0.001, pg ¼ 0.95, pi ¼ 0.50
Control 7.6  0.2 8.8  0.2 8.8  0.3
pH
Esmolol 7.44  0.01 7.42  0.01 7.43  0.02 pw ¼ 0.23, pg ¼ 0.94, pi ¼ 0.63
Control 7.43  0.01 7.41  0.01 7.44  0.01
pO2 (kPa)
Esmolol 14.3  1.5 17.0  1.1 14.7  1.2 pw ¼ 0.86, pg ¼ 0.70, pi ¼ 0.13
Control 16.2  2.1 14.3  0.9 16.9  0.6
pCO2 (kPa)
Esmolol 5.5  0.1 6.1  0.2 5.6  0.3 pw ¼ 0.052, pg ¼ 0.57, pi ¼ 0.99
Control 5.7  0.2 6.1  0.2 5.7  0.2
HCO3
- (mmol/L)
Esmolol 27.5  0.6 28.8  0.6 28.2  0.6 pw ¼ 0.21, pg ¼ 0.67, pi ¼ 0.56
Control 27.9  0.4 28.5  0.4 28.9  1.2
s-Kþ (mmol/L)
Esmolol 4.5  0.1 4.9  0.1 5.6  0.1 pwo 0.001, pg ¼ 0.36, pi ¼ 0.33
Control 4.4  0.1 4.9  0.1 5.4  0.1
s-Naþ (mmol/L)
Esmolol 139  1 138  1 138  1 pw ¼ 0.21, pg ¼ 0.39, pi ¼ 0.73
Control 140  1 139  1 138  2
NOTE. Values are mean  SEM, n ¼ 10.
Abbreviations: MAP, mean aortic pressure; pg, p value for between groups from two-way RM-ANOVA; pi, p value for interaction from two-way
RM-ANOVA; pw, p values for within subjects from two-way RM-ANOVA; RM-ANOVA, repeated-measures analysis of variance; s, serum levels;
Temprect, rectal temperature.
DAHLE ET AL690The logarithmic ﬁtted end-diastolic pressure-volume relationship, β,
increased in both groups from 1 to 2 hours (po 0.001) and further
increased at 3 hours (po 0.01) with no signiﬁcant differences
between groups.
Tissue and Blood Samples
Arterial blood gases were within physiologic ranges
during reperfusion with no differences between groups. Myocardial
tissue water content in esmolol-treated animals was 80.4  0.1%
compared to controls 80.8 %  0.1 (p = 0.04). There were no
signiﬁcant differences in myocardial blood ﬂow between groups in
left and right ventricular tissue measured by microspheres between
groups 1, 2, and 3 hours after reperfusion (Table 4). The level of
cleaved caspase-3 was lower in the left ventricular subendocardial
wall layer in the esmolol group compared to controls (p ¼ 0.02)
(Fig 4). However, caspase-3 activity did not show any signiﬁcant
difference between groups in wall layers. Three hours after aortic
declamping, troponin-T was 339  48 ng/L for the esmolol group
and 357  55 ng/L for the control group (p ¼ 0.81).
DISCUSSION
The main ﬁnding in this study was that the addition of
esmolol to repeated, cold, oxygenated blood cardioplegic
solution preserves the left ventricular contractile function in this
clinically relevant animal model with 100 minutes of cardiople-
gic arrest and 3 hours of reperfusion.Both EF and radial peak systolic TDI strain in the subendocar-
dium were better preserved 3 hours after declamping in the esmolol
group compared to the control group. These variables, describing left
ventricular systolic function, are both pre- and afterload dependent.26
However, LV-EDVi, LV-EDP, and MAP did not differ between
groups, demonstrating comparable loading conditions. Furthermore,
in the esmolol-treated animals, there was an increased dP/dtmax as
well as an increased subendocardial and midmyocardial strain rate 3
hours after declamping (Figs 2 and 3). These variables are more
load-independent compared to strain.26 Also, in the esmolol-treated
animals the load-independent variable PRSW clearly increased from
1 to 3 hours after declamping and weaning to levels signiﬁcantly
higher at 3 hours compared to controls. Together with an overall
better-preserved cardiac index, all of these ﬁndings demonstrated
increased contractility when esmolol is added to the cardioplegic
solution. The slope of ESPVR, however, did not show a similar
pattern. One explanation for this could be that at low ventricular
pressures and volumes this relation is often nonlinear, making the
forced ﬁtting of a linear model more inaccurate.22 This also is
reﬂected by the variability of ESPVR in the present study.
The preserved contractile function in the esmolol group is
consistent with a more sensible adrenergic receptors apparatus.
During CPB a stress response with a corresponding rise in serum
catecholamines occur.27,28 In addition, endogenous norepinephrine
may be released in the myocardium as a response to anoxia and
cooling during cardioplegic arrest.11–13 Furthermore, this adrenergic
Table 4. Cardiac and Hemodynamic Variables and Tissue Blood Flow 1, 2, and 3 Hours After Aortic Declamping
Variable 1 hour 2 hours 3 hours Statistics
HR (beat/min)
Esmolol 107  6 123  9 130  10 pw ¼ 0.001, pg ¼ 0.33, pi ¼ 0.66
Control 98  8 107  9 119  11
LV-ESP (mmHg)
Esmolol 87  5 69  2 70  3 pw ¼ 0.001, pg ¼ 0.56, pi ¼ 0.34
Control 84  6 76  4 72  3
LV-ESVi (mL/m
2)
Esmolol 24  3 19  3 15  2 pw ¼ 0.010, pg ¼ 0.33, pi ¼ 0.50
Control 22  3 20  3 17  2
LV-EDP (mmHg)
Esmolol 7.4  0.7 5.6  0.7 5.9  0.8 pw ¼ 0.011, pg ¼ 0.70, pi ¼ 0.19
Control 6.3  0.7 5.9  0.6 5.6  0.8
LV-EDVi (mL/m
2)
Esmolol 59  4 51  4 46  3 pwo 0.001, pg ¼ 0.64, pi ¼ 0.92
Control 62  4 53  4 47  4
SVi (mL/m
2)
Esmolol 34  3 31  3 30  2 pwo 0.001, pg ¼0.50, pi ¼ 0.077
Control 41  3 33  2* 29  2*†
LV-SWi (mmHg/mL/m
2)
Esmolol 2691  304 2049  176 2079  168 pw ¼ 0.001, pg ¼0.90, pi ¼ 0.22
Control 2902  299 2251  182 1757  146
LV-dP/dtmin (mmHg/s)
Esmolol -1954  206 -1630  131 -1685  126 pw ¼ 0.002, pg ¼ 0.94, pi ¼ 0.43
Control -1999  199 -1674  146 -1554  106
β (unit-less)
Esmolol 0.034  0.004 0.052  0.010 0.062  0.010 pw ¼ 0.005, pg ¼0.39, pi ¼ 0.14
Control 0.038  0.005 0.038  0.005 0.047  0.010
EDPVRlin (mmHg/mL)
Esmolol 0.16  0.03 0.16  0.02 0.21  0.03 pw ¼ 0.018, pg ¼0.31, pi ¼ 0.60
Control 0.14  0.01 0.14  0.02 0.17  0.02
MAP (mmHg)
Esmolol 72  6 56  1 53  2 pwo 0.001, pg ¼0.26, pi ¼ 0.67
Control 79  7 63  4 57  3
CVP (mmHg)
Esmolol 5.0  0.7 4.3  0.7 4.4  0.7 pwo 0.001, pg ¼0.50, pi ¼ 0.42
Control 5.9  0.9 4.8  0.9 5.3  0.9
PAP (mmHg)
Esmolol 20  1 17  1 18  1 pw ¼ 0.69, pg ¼0.40, pi ¼ 0.86
Control 18  1 16  1 16  2
LV-tissue ﬂow (mL/min/g)
Esmolol 1.17  0.10 1.11  0.09 1.18  0.08 pw ¼ 0.13, pg ¼0.10, pi ¼ 0.31
Control 1.08  0.08 0.91  0.07 0.94  0.08
RV-tissue ﬂow (mL/min/g)
Esmolol 1.17  0.14 1.07  0.13 1.25  0.11 pw ¼ 0.016, pg ¼0.23, pi ¼ 0.42
Control 1.08  0.07 0.89  0.07 1.03  0.08
NOTE. Values are mean  SEM.
Abbreviations: β and EDPVRlin, slope of logarithmic and linearly ﬁtted end-diastolic pressure-volume relationship; CVP, mean central venous
pressure; dP/dtmin, peak minimum of ﬁrst derivative of ventricular pressure; EDP, end-diastolic pressure; EDV, end-diastolic volume; ESP, end-
systolic pressure; ESV, end-systolic volume; HR, heart rate; i, value indexed for body surface area; LV, left ventricle; MAP, mean arterial pressure;
PAP, mean pulmonary artery pressure; pg, p value for between groups from two-way RM-ANOVA; pi, p values for interaction from two-way RM-
ANOVA; pw, p values for within subjects from two-way RM-ANOVA; RM-ANOVA, repeated-measures analysis of variance; RV, right ventricle; SV,
stroke volume; SW, stroke work.
*Signiﬁcant difference within group means from 1 hour.
†Signiﬁcant difference within group means from 2 hours.
ESMOLOL PRESERVES CARDIAC FUNCTION AFTER CPB 691stimulation triggers desensitization of β-adrenergic receptors via G-
protein uncoupling as shown in both animal experiments as well as
in clinical studies.29,30 Esmolol has been shown to alleviate β-
adrenergic receptor desensitization when given as a continuous
infusion during CPB.10 This also may explain the more rapid
isovolumetric relaxation observed by reduction of τ in the esmololgroup, because the isovolumetric relaxation is enhanced by β-
adrenergic stimulation via mobilization of cytosolic Ca2þ.
Myocardial tissue blood ﬂow did not differ between groups.
However, there was a tendency of decreasing blood ﬂow in the
control group. This is in agreement with the differences seen in
systolic function. Therefore, an enhanced adrenergic response
Fig 4. Cleaved caspase-3 relative to GAPDH and caspase-3 activ-
ity trough the left ventricular myocardial wall layers 3 hours after
aortic declamping. Bars are mean þ SEM. * ¼ signiﬁcant difference
between groups by two-sample t-test.
DAHLE ET AL692to the decline in loading conditions rather than alleviated
myocardial stunning could explain the hemodynamic differ-
ences between groups.
A modest amount of esmolol added to an existing cardioplegic
regimen, may be an appealing strategy to utilize the potential
protective effects of β-adrenergic receptor blocking agents.
Experimentally, esmolol administered as pretreatment or at
declamping improves cardiac function after CPB and cardioplegic
arrest.8–10 However, in these studies the myocardium only is
exposed to esmolol for a limited period of time. By adding
esmolol to the cardioplegic perfusate, the authors aimed at
exposing the myocardium during the entire cross-clamp time,
counteracting both potential ischemic and lethal reperfusion injury
and desensitization of β-adrenergic receptors by endogenous
catecholamine release. The half-life for esmolol in blood is only
9 minutes because of the rapid degradation with blood esterases.31
Consequently, the cardioplegic solution must be administered with
a dual-head pump mixing blood and the cardioplegic concentrate
at the time of delivery. The route of administration also allowed
exposing the myocardium to relatively high doses of esmolol but
only adding up to low systemic concentrations. This, in combi-
nation with the fact that the ﬁnal cardioplegic perfusion was
completed 18 minutes before aortic declamping, should minimize
the danger of signiﬁcant accumulation of esmolol during weaningthat could hamper cardiac performance in the early
postoperative phase.
A small but signiﬁcant difference in cleaved caspase-3
levels in the subendocardial wall layer of esmolol-treated
animals indicated some degree of protection against apoptosis.
This may be initiated either by ischemia or by lethal reperfu-
sion injury.32 However, no signiﬁcant differences between
groups were found in troponin-T release 3 hours after
declamping. This contradicts that the addition of esmolol to
the cardioplegic solution reduced reperfusion induced injury.
The small but signiﬁcant difference in myocardial water
content between groups observed in the current study agreed
with several studies showing strong correlations between
myocardial water content and the reduction in myocardial
contractility, increased isovolumetric relaxation and increased
diastolic stiffness.33–35 The mechanism underlying this corre-
lation is not understood clearly, but altered compliance and
reduced diffusion because of an expansion in the interstitium
have been suggested.36
It should be noted that high concentrations of esmolol may
alter isolated myocyte membrane potentials through blocking of
L-type Ca2þ channels and fast Naþ channels, resulting in direct
negative inotropic effects beyond the β-adrenergic receptor
antagonism.18,37 In the present study, the myocardium was
exposed to relatively high concentrations of esmolol. During the
high-dose cardioplegic perfusion (Table 1) the calculated concen-
tration of esmolol in the freshly mixed cardioplegic solution was
34 mM. This was just within the margins of what also may
contribute to blocking of Naþ and Ca2þ channels in myocytes,
which in turn could contribute to keep the myocardial membrane
potential closer to resting values, potentially enhancing protective
effects of the cardioplegia.
Limitations
This study was performed using a porcine model with young,
healthy pigs and clinical interpretations should be carried out with
care. Relatively few animals were studied, but with a strict and
standardized protocol to obtain maximal statistical power. Smaller
differences and more biologic variance could be expected in a
clinical setting including individual supportive treatment. For both
groups of pigs, a gradual decay in cardiovascular loading conditions
after weaning was indicated by the reductions in systemic and left
ventricular pressures, left ventricular volumes, and the increase in
heart rate. No individual vasoactive support beyond the stand-
ardized continuous saline infusion was allowed in the protocol.
Also, from previous experience the authors knew that the current
model would deteriorate over time, which was the reason for only 3
hours of observation time after aortic declamping. On the other
hand, the cardiac response to these altered loading conditions very
well may have accentuated the difference in contractile response
and, thus, revealed the difference between the 2 groups.
CONCLUSION
The current study demonstrated that the addition of esmolol to
repeated, cold, oxygenated blood cardioplegia preserved systolic
function the ﬁrst 3 hours after aortic declamping in a porcine model
with 100 minutes of cardioplegic arrest. The study can contribute to
the attempts to improve and optimize the myocardial protection
ESMOLOL PRESERVES CARDIAC FUNCTION AFTER CPB 693properties of repeated, cold, oxygenated blood cardioplegia. The
technique for administering cardioplegia with esmolol used in the
present study does not require any additional instrumentation or
time, and easily could be adapted in a clinical trial and eventually
also into clinical practice.ACKNOWLEDGMENTS
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